Selected article for: "antiviral activity and drug resistant mutant"
Author: White, Kris M.; Rosales, Romel; Yildiz, Soner; Kehrer, Thomas; Miorin, Lisa; Moreno, Elena; Jangra, Sonia; Uccellini, Melissa B.; Rathnasinghe, Raveen; Coughlan, Lynda; Martinez-Romero, Carles; Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Fabius, Jacqueline M.; Obernier, Kirsten; Dejosez, Marion; Guillén, María José; Losada, Alejandro; Avilés, Pablo; Schotsaert, Michael; Zwaka, Thomas; Vignuzzi, Marco; Shokat, Kevan M.; Krogan, Nevan J.; García-Sastre, Adolfo
Title: Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
  • Cord-id: mj3gdjxj
  • Document date: 2021_2_26
    • ID: mj3gdjxj
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistan
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and addition time: 1
    • absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • absence presence and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • action different mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2
    • acute sars cov respiratory syndrome coronavirus and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and addition time assay: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and additive effect: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and adenovirus transduction: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung inflammation reduce: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lung inflammation reduction: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and lung sars replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung titer: 1, 2, 3, 4, 5, 6, 7